DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-597/S-045
NDA 50-575/S-038
NDA 50-726/S-020
NDA 50-725/S-026

GlaxoSmithKline
Attention: Deneen Stewart, Ph.D.
Associate Director, US Regulatory Affairs
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101-7929

Dear Dr. Stewart:

Please refer to your supplemental new drug applications dated January 12, 2007, received January 12, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for:

NDA 50-597/SLR-045: AUGMENTIN® (amoxicillin/clavulanate potassium) Chewable Tablets, 125 mg and 250mg
NDA 50-575/SLR-038: AUGMENTIN® (amoxicillin/clavulanate potassium) Powder for Oral Suspension 125 mg and 250 mg
NDA 50-726/SLR-020: AUGMENTIN® (amoxicillin/clavulanate potassium) Chewable Tablets, 200 mg/5 mL and 400 mg/5 mL
NDA 50-725/SLR-026: AUGMENTIN® (amoxicillin/clavulanate potassium) Powder for Oral Suspension, 200 mg/5 mL and 400 mg/5 mL

These applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

These "Changes Being Effected" supplemental new drug applications provide for revisions to the **WARNINGS** and **PRECAUTIONS/Information for Patients** sections to include information on *Clostridium difficile* associated disease (CDAD).

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on January 12, 2007.

We note that your January 12, 2007 submission includes final printed labeling (FPL) for your package insert. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, MD, Regulatory Project Manager, at (301) 796-0803.

Sincerely,

{See appended electronic signature page}

Katherine A. Laessig, M.D.
Deputy Director
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Labeling submitted on January 12, 2007

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kathrine Laessig
3/27/2008 02:11:51 PM